Wedbush on Tuesday reiterated its Outperform rating and 12-month price Target of $7 for Aprea Therapeutics, Inc. (APRE), a clinical-stage biopharmaceutical company. The company's lead product candidates are APR-1051, in a Phase 1 clinical trial for the treatment of patients with advanced solid tumours with biomarkers, and ATRN-119, in Phase 1/2a clinical trials for solid tumour indications. On Monday, Aprea announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing totalling approximately $30 million in gross proceeds, and also highlighted positive emerging clinical activity for APR-1051 in the ongoing Phase 1 trial in patients with advanced solid tumours harbouring cancer-associated genetic alterations, dubbed the ACESOT-1051 trial. Commenting on the clinical trial updates of APR-1051, analyst Robert Driscoll said, "We look forward to additional updates in 2Q:26. Overall, we view the confirmed response as continued validation for APR-1051 in patients with specific genetically defined cancers and noted, 'APR-1051 continues to be well tolerated, with most AEs being Grade 1 or Grade 2" The APR-1051 dose-escalation study is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026. This study will include patients with uterine serous carcinoma, colorectal and HPV+ tumours..APRE has traded between $0.54 and $2.30 in the last year. APRE is currently trading at $0.78, up 5.98%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.